Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P02549
UPID:
SPTA1_HUMAN
Alternative names:
Erythroid alpha-spectrin
Alternative UPACC:
P02549; Q15514; Q5VYL1; Q5VYL2; Q6LDY5
Background:
Spectrin alpha chain, erythrocytic 1, also known as Erythroid alpha-spectrin, is a pivotal component of the cytoskeletal network underpinning the erythrocyte plasma membrane. It collaborates with band 4.1 and actin to establish the erythrocyte plasma membrane's cytoskeletal superstructure, playing a crucial role in maintaining cell shape and integrity.
Therapeutic significance:
This protein is implicated in several hematologic disorders, including Elliptocytosis 2, Hereditary pyropoikilocytosis, and Spherocytosis 3, all characterized by hemolytic anemia and abnormal erythrocyte shapes. Understanding the role of Spectrin alpha chain, erythrocytic 1, could open doors to potential therapeutic strategies for these conditions.